Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer

2019 ◽  
Author(s):  
Keyword(s):  
Lung Cancer ◽  
Esophageal Cancer ◽  
Clinical Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Advanced Esophageal Cancer ◽  
Small Cell Lung

scholarly journals Amrubicin therapy improves patients with refractory small-cell lung cancer: A single-arm confirmatory Chinese clinical study

2016 ◽  
Vol 11 (3) ◽  
pp. 564
Author(s):  
Mengli Zheng ◽  
Naikang Zhou ◽  
Lianjun Ma ◽  
Wenbo Jin
Keyword(s):  
Lung Cancer ◽  
Clinical Study ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Elevated Serum ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Serum Transaminases ◽  
Rate Of Response

<p class="Abstract">Our objective was to evaluate an open-label, multicenter, single-arm study to appraise whether amrubicin therapy improves patients with refractory small-cell lung cancer in Chinese clinical study. Patients (n=95) with refractory small-cell lung cancer received 3 consecutive days amrubicin therapy for 21 days. Overall response rate of response to amrubicin was 39%. Anemia, febrile neutropenia, thrombocytopenia, hyperglycemia, hyponatremia, infection, elevated serum transaminases levels were appeared, but the incidences of adverse events were very few. Our results suggest amrubicin therapy can improve patients with refractory small-cell lung cancer and may be an effective and safe treatment option.</p><p> </p>

Sign in / Sign up

Export Citation Format

Share Document